Profound Medical Corp.
Profound Medical Corp. develops and commercializes MRI-guided, incision-free therapies for treating diseased tissue, centered on its TULSA-PRO and Sonalleve systems. The company is organized around a holding-company structure with operating subsidiaries and serves hospitals, clinics, and physician-led treatment centers in North America, Europe, and Asia.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueMRI-guided prostate therapy systems used for incision-free ablation procedures.
MRI-guided ablation systems marketed mainly outside North America.
One-time-use devices consumed per patient treated on installed systems.
Genius services, procedure support, warranties, and maintenance services.
Products
Reported · share of revenue- Recurring Non Capital60.4 %
- Capital Equipment39.6 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Profound sells to hospitals, clinics, and other end-users that perform MRI-guided procedures, often through a mix of direct sales and distributor channels. The buying decision is driven by clinical adoption, compatibility with installed MRI scanners, reimbursement support, and the ability to offer less invasive treatment options to patients.
Buy TULSA-PRO or Sonalleve systems and recurring consumables to perform MRI-guided procedures.
Influence product adoption, procedure protocols, and ongoing clinical utilization.
Purchase and resell products in markets where Profound lacks direct sales coverage.
Philips, Siemens, and GE-related channels support lead generation and distribution.
Strategy
Profound’s strategy is to expand adoption of TULSA-PRO and Sonalleve by building direct sales capability, supporting clinicians, and increasing utilization of installed systems. It also relies on partnerships with MRI scanner manufacturers and clinical evidence generation to improve reimbursement support and broaden market acceptance.
Installed-base utilization and procedure volume drive recurring device and service revenue.
Coverage by government and private payors supports broader clinical adoption.
MRI ecosystem partners help generate leads and reduce commercialization friction.
Wider MRI compatibility and new applications can enlarge the addressable market.
Geography
Q1/2026Profound has generated revenue in the United States, Europe, and Asia, with the United States using a hybrid recurring model and international markets relying more on capital sales plus recurring consumables. Its systems are compatible with select MRI scanners from Philips, Siemens, and GE Healthcare, which makes geographic expansion dependent on regulatory approvals, local distribution, and installed MRI ecosystems.
Share of the revenue the company reports by geography.
Risks
Profound depends on physician adoption, reimbursement support, and continued regulatory clearance for its MRI-guided therapies. Its commercialization model also exposes it to supplier concentration, distributor credit risk, and reliance on third-party MRI scanner partners for market access and compatibility.
- Physician and clinician adoption riskImpact: HighLikelihood: Medium
The systems require clinical acceptance and procedural use to generate recurring revenue.
Exposure: TULSA-PRO and Sonalleve commercialization
- Reimbursement and coverage riskImpact: HighLikelihood: Medium
Coverage by government and private payors affects market uptake and procedure economics.
Exposure: Clinical evidence and reimbursement efforts
- Single-source supplier dependenceImpact: HighLikelihood: Medium
Some components are sourced from a single supplier, creating supply and quality risk.
Exposure: TULSA-PRO and Sonalleve components
- MRI compatibility and partner dependenceImpact: HighLikelihood: Medium
Commercial success depends on compatibility with select MRI scanners and partner promotion.
Exposure - Distributor credit and collection riskImpact: MediumLikelihood: Medium
Open-credit sales and international distributor terms can delay or impair cash collection.
Exposure: International distributor channels
Accounting
Judgemental itemsCapital equipment, one-time-use devices, and services may be recognized differently.
Impact: Affects quarterly revenue mix and comparability
Distributor sales on open credit require judgment about collectability.
Impact: Affects receivables and bad debt expense
Capital sales can be lumpy relative to recurring device revenue.
Impact: Affects reported growth and margin patterns
The company references share-based compensation in operating expense growth.
Impact: Affects SG&A and R&D expense levels
Similar listed companies
Publicly listed companies with a comparable business focus.
Hyperfine, Inc.
HYPR · Electromedical & Electrotherapeutic Apparatus
Sensus Healthcare, Inc.
SRTS · Surgical & Medical Instruments & Apparatus
Fonar Corp
Electromedical & Electrotherapeutic Apparatus
FONAR Corp designs, manufactures, sells, and services MRI scanners, with a distinctive focus on its Upright® MRI system that can image patients in weight-bearing positions.
Profusa, Inc.
NVACW · Surgical & Medical Instruments & Apparatus
ProPhase Labs, Inc.
PRPH · Pharmaceutical Preparations
iRadimed Corporation
IRMD · Surgical & Medical Instruments & Apparatus
IRADIMED Corp designs and sells MRI-compatible medical devices used inside scanner rooms, centered on infusion pumps, patient vital signs monitoring systems, and related disposables and service.
Last updated: 24/09/2026